1. Home
  2. NDLS vs COCH Comparison

NDLS vs COCH Comparison

Compare NDLS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$13.52

Market Cap

68.7M

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.69

Market Cap

51.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
COCH
Founded
1995
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Blank Checks
Sector
Consumer Discretionary
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
51.0M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
NDLS
COCH
Price
$13.52
$0.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
20.4K
49.4K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.45
EPS
N/A
N/A
Revenue
$495,089,000.00
$241,000.00
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
7.11
52 Week Low
$0.47
$0.36
52 Week High
$19.00
$1.89

Technical Indicators

Market Signals
Indicator
NDLS
COCH
Relative Strength Index (RSI) 41.19 42.99
Support Level $12.83 $0.63
Resistance Level $13.95 $0.74
Average True Range (ATR) 0.73 0.03
MACD -0.09 -0.00
Stochastic Oscillator 23.12 11.33

Price Performance

Historical Comparison
NDLS
COCH

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: